Merck’s monopoly on a blockbuster diabetes ... and a law professor at University of California College of the Law, San ...

Merck & Co is among the partners behind a consortium ... Hannan Parvisian, CEO and co-founder of San Francisco-based Volans-i, said: “Successfully demonstrating our ability to make temperature ...

It has shifted commercial manufacturing off Genentech's South San Francisco campus ... Genentech also makes some drugs there for Merck & Co. Inc. Lonza will phase out manufacturing of those ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

U.S. index futures fell in premarket trading on Tuesday after the Dow Jones ended a three-day winning streak. Investors are ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Jesse is Principal and South San Francisco Office Head at GCI General ... Nordisk, Corteva, Merck, GSK, AstraZeneca, and Pfizer. What’s next for the Peninsula's life science real estate market?

Collaborations with Merck, Vaxcyte, and Astellas Pharma could ... company founded in 2003 and headquartered in South San Francisco. STRO develops antibody-drug conjugates [ADCs] for oncology ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...